GSK: Cervical cancer vaccine protects for more than five years

04/17/2007 | Forbes

GlaxoSmithKline released new data showing its cervical cancer vaccine Cervarix prevents pre-cancerous lesions caused by two viruses for five and a half years. GSK has applied to U.S. and European regulators for approval of the vaccine, which would compete with Merck's Gardasil.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA